Drugging the undruggable

One of the main limitations of the many knockout and knockdown screens used in identifying new drug targets is that they don't allow protein expression and therefore reveal no information about how to drug the targets, many of which go nowhere. By operating at the protein level to disrupt function, PhoreMost Ltd. has developed a platform to discover new targets and find ways to drug those previously written off as "undruggable."

"Drugging what most people consider undruggable targets is the next big barrier for pharma," said CEO Chris Torrance...